Jobs / United States / Gilead Sciences INC
Director, Global Value & Access Strategy (Cell-Therapy Autoimmune)
Gilead Sciences INC · 🇺🇸 3 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 159 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 75 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Gilead Sciences INC paid sponsored hires in similar roles3 certified filings for “Director, Global Program Management” (Project Management Specialists) in CA: $165k–$213k, median $213k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Gilead Sciences INC
The US Department of Labor certified 159 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 75 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Gilead Sciences INC →
About the role
We’re here for one reason and one reason only – to cure cancer. Every moment is dedicated to developing treatments and every action moves us one step closer to our goal. We’ve made incredible scientific breakthroughs and our pioneering personalized CAR T-cell therapies have changed the paradigm. But we're not finished yet. Join Kite, as we make even bigger advances in cancer therapies, and help shape where our business and medical science goes next. We believe every employee deserves a great leader. People Leaders are the cornerstone to the employee experience at Gilead and Kite. As a people leader now or in the future, you are the key driver in evolving our culture and creating an environment where every employee feels included, developed and empowered to fulfil their aspirations. Join Kite and help create more tomorrows. Job Description We are seeking a Director, Global Value & Access Strategy (GVAS), Cell-therapy Autoimmune. This role reports to the Senior Director, GVA Lead, Lymphoma, Autoimmune and Solid Tumors/Pipeline. This role will be office-based/hybrid (3 days onsite) in El Segundo or Thousand Oaks or Foster City, CA. In this position, you will be a critical Global Value & Access partner for Kite's growing autoimmune cell therapy portfolio. You will lead the development and execution of global market access strategies to support early and late-stage development programs, while preparing for future launches of transformative cell therapies across autoimmune diseases. You will work closely with Global Clinical Development, Medical Affairs, HEOR/RWE, Commercial, Regulatory Affairs and regional Access teams to ensure payer perspectives are incorporated into development decisions and launch planning. You will play a key role in shaping evidence generation strategies that support differentiated value propositions, reimbursement, and patient access across major global markets. Key Responsibilities Strategic Market Access Leadership • Serve as the Global Market Access representative for assigned autoimmune programs and contribute to cross-functional conversations. • In the Value Access Sub-Team, you will be leading and partnering with the Global and Regional functions of Value Access, HEOR/RWE and commercial to ensure efficient integration of Access input into the Portfolio Strategy. • Lead the development of global value and access strategies across the product lifecycle, from early development through launch and lifecycle management. • Ensure payer, HTA, and health system perspectives are reflected in development, evidence generation, pricing, and commercialization strategies. • Partner with regional and country access teams to develop integrated global-to-local reimbursement strategies. Asset Development and Evidence Generation • Analyze market access trends, evolving reimbursement requirements, competitive dynamics, and health system considerations across major markets including the US, EU5, Canada, Australia, and Japan. • Provide market access input into target product profiles, clinical development plans, endpoint selection, comparator strategy, study design, and evidence generation plans. • Advise development teams on evidence requirements needed to support future reimbursement, pricing, and formulary access decisions. • Ensure access-relevant considerations are incorporated into development milestones and governance decisions. Value Demonstration and HEOR Partnership • Partner with Clinical, HEOR, RWE and Medical Affairs to develop and execute early payer engagement and HTA scientific advice strategies across multiple autoimmune indications, ensuring payer perspectives are incorporated into evidence generation and development plans. • Provide strategic leadership on US market access dynamics across